Alumis Inc.（ALMS）股票分析ALMSAlumis Inc.

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alumis Inc. is a good buy right now due to its recent price recovery of 10.78% over the last five days and a current RSI of 53.33, suggesting it is neither overbought nor oversold. The stock has shown resilience despite a challenging year, with a 40.96% increase over the past year. However, the main risk is the substantial insider selling, which has increased by 586.17%, indicating potential concerns among insiders about the company's future performance.